Antitumor Activity of Free and Liposome-entrapped Annamycin, a Lipophilic Anthracycline Antibiotic with Non-Cross-Resistance Properties

Cancer Research

Volumn 54, Issue 6, 1994, Pages 1479-1484

  Soler, Roman Perez ^a   Van, Nguyen T ^a   Priebe, Waldemar ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DOXORUBICIN; LIPOSOME;

ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; DRUG EFFECT; DRUG EFFICACY; GROWTH INHIBITION; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LIPID SOLUBILITY; LIPOPHILICITY; LUNG CARCINOMA; LUNG METASTASIS; MALE; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETICULOSARCOMA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; CHEMISTRY, PHYSICAL; DOXORUBICIN; DRUG RESISTANCE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; KB CELLS; LEUKEMIA P388; LIPOSOMES; LUNG NEOPLASMS; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHENOTYPE; TUMOR CELLS, CULTURED;

EID: 23444443192     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. De Vita, V.T., Hellman, S., and Rosenberg, S. (eds.). Principles and Practice of Oncology, Ed. 4. Philadelphia: J.B. Lippincott Co., 1993.
2. Coley, H.M., TWentyman, P.R., and Workman, P. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur. J. Cancer, 6: 665-667, 1990.
3. Horichi, N., Tapiero, H., Sugimono, Y., Bungo, M., Nishiyama, M., Fourcade, A., Lampidids, T.J., Kasahara, K., Sasaki, Y., Takahashi, T., and Saijo, N. 3′-Deamino-3′-morpholino-13-deoxo-10-hydroxycanninomycin conquers multidrug resistance by rapid influx following higher frequency of formation of DNA single- and doublestrand breaks. Cancer Res., 50: 4698-4701, 1990.
4. Acton, E.M., Tong, G.L., Mosher, C.W., and Wolgemuth, R.L. Intensely potent morpholinyl anthracyclines. J. Med. Chem., 27: 638-645, 1984.
5. Coley, H.M., Twentyman, P.R., and Workman, P. Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines, and further resistance modification by verapamil and cyclosporin A. Cancer Chemother. Pharmacol., 24: 284-290, 1989.
6. Ganapayhi, R., Grabowski, D., Sweatman, T.W., Seshadri, R., and Israel, M. N-Ben-zyladriamycin-14-valerate versus progressively doxorubicin-resistant murine tumors: cellular pharmacology and characterization of cross-resistance in vitro and in vivo. Br. J. Cancer, 60: 819-826, 1989.
7. Barbieri, B., Giuliani, F.C., Bordoni, T., Casazza, A.M., Geroni, C., Bellini, O., Suarato, A., Gioia, B., Penco, S., and Arcamone, F. Chemical and biological characterization of 4′-iodo-4′-deoxydoxorubicin. Cancer Res., 47: 4001-4006, 1987.
8. Priebe, W., Van, N.T., Burke, T.G., and Perez-Soler, R. Removal of the basic center from doxorubicin partially overcomes multidrug resistance and decreases cardiotoxicity. Anticancer Drugs, 4: 37-48, 1993.
9. Wassermann, K., Markovits, J., Jaxel, C., Capranico, G., Kohn, K.W., and Pommier, Y. Effects of morpholinyl doxorubicins, doxorubicin, and actinomycin D on mammalian DNA topoisomerases I and II. Mol. Pharmacol., 38: 38-45, 1990.
10. Zwelling, L.A., Altschuler, E., Cherif, A., and Farquhar, D. W-(5, 5-Diacetoxypentyl)-doxorubicin: a novel anthracycline producing DNA interstrand cross-linking and rapid endonucleolytic cleavage in human leukemia cells. Cancer Res., 51: 6704-6707, 1991.
11. Perez-Soler, R., and Priebe, W. Anthracycline antibiotics with high liposome entrapment structural features and biological activity. Cancer Res., 50: 4260-4266, 1990.
12. Ganzina, F., Pacciarini, M.A., and DiPietro, N. Invest. New Drugs, 4: 85, 1986.
13. Horton, D., and Priebe, W. Oxyhalogenation of glycals for the synthesis of antitumor active 2′-halo daunorubicin analogs. Carbohydr. Res., 136: 391-396, 1985.
14. French Epirubicin Study Group. J. Clin. Oncol., 6: 679-688, 1988.
15. Ling, Y.H., Priebe, W., Yang, L.Y., Burke, T.G., Pommier, Y., and Perez-Soler, R. in vivo cytotoxicity, cellular pharmacology, and DNA lesions induced by Annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res., 53: 1583-1589, 1993.
16. Zou, Y., Priebe, W., Ling, Y., and Perez-Soler, R. Organ distribution and tumor uptake of annamycin, a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemother. Pharmacol., 32: 190-196, 1993.
17. Horton, D., and Priebe, W. 4-Demethoxy-3′-desamino-2′-halo anthracyclines and pharmaceutical composition containing same. US Patent 4, 537, 882, August 27, 1985.
18. Zou, Y., Hayman, A., Priebe, W., and Perez-Soler, R. Quantitative analysis of the lipophilic doxorubicin analogue Annamycin in plasma and tissue samples by reversephase chromatography. J. Pharm. Sci., 82: 1151-1154, 1993.
19. Zou, Y., Gu, X., Ueno, M., and Horikoshi, I. The quantitative analysis of Adriamycin and liposomal Adriamycin injected into hepatic artery in vivo. J. Shenyang Coll. Pharm., 9: 6-10, 1992.
20. Akiyama, S., Fojo, A., and Hanover, J.A. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat. Cell Mol. Genet., 11: 117- 126, 1985.
21. Shen, D.W., Cardarelli, C., and Hwang, J. Multiple drug-resistant human KB carcinoma cells independently selected for high-level resistance to colchicine, Adriamycin, or vinblastine show changes in expression of specific proteins. J. Biol. Chem., 261: 7762-7770, 1986.
22. Epstein, J., Xiao, H., and Oba, B.K. P-glycoprotein expression in plasma cells. Blood, 74: 913-917, 1989.
23. Dalton, W.S., Grogan, T.M., Rybski, J.A., et al. Immunohistochemical detection and quantitation of P-glycoprotein in multiple drug resistant human myeloma cells: association with level of drug resistance and drug accumulation. Blood, 73: 747-752, 1989.
24. Coley, H.M., Twentyman, P.R., and Workman, P. Identification of anthracyclines and related agents that retain preferential activity over Adriamycin in multidrug-resistant cell lines, further resistance modification by verapamil and cyclosporin A. Cancer Chemother. Pharmacol., 24: 284-290, 1989.
25. Green, L.M., Reade, J.L., and Ware, C.F. Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines. J. Immunol. Methods, 70: 257-268, 1984.
26. Casazza, A.M. Screening for anthracycline analogues. In: K. Hellmann and S.K. Carter (eds.), Fundamentals of Cancer Chemotherapy, pp. 155-158. New York: McGraw-Hill Book Co., 1987.
27. Thierry, A.R., Jorgensen, T.J., Forst, D., Belli, J.A., Dritschilo, A., and Rahman, A. Multidrug resistance in Chinese hamster cells: effect of liposome-encapsulated doxorubicin. Cancer Commun., 1: 311-316, 1989.
28. Fan, D., Bucana, C.D., O'Brian, C.A., Zwelling, L.A., Seid, C., and Fidler, I.J. Enhancement of murine tumor cell sensitivity to Adriamycin by presentation of the drug in phosphatidylcholine-phosphatidylserine liposomes. Cancer Res., 50: 3619-3626, 1990.
29. Oudard, S., Thierry, A., Jorgensen, T.J., and Rahman, A. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother. Pharmacol., 28: 259-265, 1991.
30. Sadasivan, R., Morgan, R., Fabian, C., and Stephens, R. Reversal of multidrug resistance in HL-60 cells by verapamil and liposome-encapsulated doxorubicin. Cancer Lett., 57: 165-171, 1991.
31. Thierry, A.R., Dritschilo, A., and Rahman, A. Effect of liposomes on P-glycoprotein function in multidrug resistant cells. Biochem. Biophys. Res. Commun., 187: asilos, 1992.
32. Rahman, A., Husain, S.R., Siddiqui, J., Verma, M., Agresti, M., Center, M., Safa, A.R., and Glazer, R.I. Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells. J. Natl. Cancer Inst., 84: 1909-1914, 1992.
33. Warren, L., Jardillier, J.C., Malarska, A., and Akeli, M.G. Increased accumulation of drugs in multidrug-resistant cells induced by liposomes. Cancer Res., 52: 3241-3245, 1992.
34. Thierry, A.R., Vige, D., Coughlin, S.S., Belli, J.A., Dritschilo, A., and Rahman, A. Modulation of doxorubicin resistance in multidrug-resistant cells by liposomes. FASEB J., 7: 572-579, 1993.
35. Mayer, L.D., Tai, L.C.L., Ko, D.S.C., Masin, D., Ginsberg, R.S., Cullis, P.R., and Bally, M.B. Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res., 49: 5922-5930, 1989.
36. Gabizon, A.A. Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. Cancer Res., 52: 891-8%, 1992.